Abion expands platform for CLDN3-targeted therapeutic candidate ‘카지노 바카라’
Abion signs 카지노 바카라 L/O term sheet with U.S.-based Antibody Drug Conjugate (ADC) developer
[by Ji, Yong Jun] Abion announced on April 28 that it has confirmed the potential to expand its bispecific T-cell engager immune-oncology platform, based on ‘카지노 바카라’ (development code), an antibody therapeutic candidate targeting Claudin 3 (CLDN3), through preclinical trials.
카지노 바카라 is an antibody therapeutic candidate designed to target CLDN3, a protein overexpressed in solid tumors. Notably, it selectively binds to CLDN3, which forms tight junctions between cancer cells in various solid cancers, including small cell lung cancer (SCLC).
Bs카지노 바카라 (anti-CLDN3xCD3, Claudin 3·CD3 bispecific T-cell inducing antibody) is a bispecific antibody candidate developed from the 카지노 바카라 antibody. Its mechanism of action involves simultaneously targeting CLDN3 and CD3, a T-cell surface protein, to induce T cells to the tumor microenvironment and induce cancer cell death.
Bispecific T cell engagers represent a next-generation immunotherapy technology that simultaneously targets T cells and tumor-associated antigens through two distinct antibody sites. This approach is currently under active development for the treatment of malignant lymphoma and multiple myeloma. It is regarded as one of the most promising therapeutic platforms, alongside chimeric antigen receptor T cells (CAR-T) therapies.
Leveraging this technological competitiveness, Abion announced on April 16 that it had signed a term sheet for the licensing out (L/O) of 카지노 바카라 with a U.S.-based antibody drug conjugate (ADC) developer. The total contract value is expected to exceed USD 800 million (approximately KRW 1.2 trillion) upon the signing of the final contract.
“We have confirmed the high safety profile of 카지노 바카라 through toxicity evaluations and obtained results demonstrating enhanced therapeutic efficacy when used in combination with anticancer chemotherapy in a non-clinical models,” an Abion official said. “We will continue to promote our technology in the global market and accelerate the L/O of our pipeline.”